FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361954181> ?p ?o ?g. }

• W4361954181 abstract "<div>Abstract<p>Panitumumab (ABX-EGF or Vectibix), the first fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR), was approved by the Food and Drug Administration for treatment of patients with metastatic colorectal cancer. Here, we report for the first time the radioimmunotherapy (RIT) of EGFR-positive human head and neck cancer in a nude mouse model using pure β⁻ emitter ⁹⁰Y-labeled panitumumab. Biodistribution and planar γ-imaging studies were carried out with ¹¹¹In-DOTA-panitumumab. The RIT efficacy of ⁹⁰Y-DOTA-panitumumab was evaluated in UM-SCC-22B tumor model. CD31, Ki67, terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling, and H&E staining were done on UM-SCC-22B tumor sections after treatment. The tumor uptake of ¹¹¹In-DOTA-panitumumab in UM-SCC-22B tumor-bearing nude mice was 26.10 ± 4.93, 59.11 ± 7.22, 44.57 ± 9.80, 40.38 ± 7.76, and 14.86 ± 7.23 % injected dose per gram of tissue at 4, 24, 72, 120, and 168 hours after injection, respectively. Immunotherapy with cold panitumumab (four doses of 10 mg/kg) did not cause significant antitumor effect. RIT with a single dose of 100 μCi ⁹⁰Y-DOTA-panitumumab caused significant tumor growth delay and improved the survival in UM-SCC-22B tumor model. A single dose of 200 μCi ⁹⁰Y-DOTA-panitumumab led to almost complete tumor regression (tumor volumes were 34.83 ± 11.11 mm³ and 56.02 ± 39.95 mm³ on days 0 and 46 after treatment, respectively). Histopathologic analysis of tumors and normal organs further validated the therapeutic efficacy and limited systemic toxicity of ⁹⁰Y-DOTA-panitumumab. The high tumor uptake and prolonged tumor retention, as well as effective therapy, reveal that ⁹⁰Y-DOTA-panitumumab may be a promising radioimmunotherapeutic agent to treat EGFR-positive solid tumors. Mol Cancer Ther; 9(8); 2297–308. ©2010 AACR.</p></div>" @default.
• W4361954181 created "2023-04-05" @default.
• W4361954181 creator A5005996455 @default.
• W4361954181 creator A5018249388 @default.
• W4361954181 creator A5021293751 @default.
• W4361954181 creator A5022268901 @default.
• W4361954181 creator A5022600083 @default.
• W4361954181 creator A5038836690 @default.
• W4361954181 creator A5047916176 @default.
• W4361954181 creator A5063512998 @default.
• W4361954181 date "2023-03-31" @default.
• W4361954181 modified "2023-10-18" @default.
• W4361954181 title "Data from Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using ⁹⁰Y-Labeled Fully Human Antibody Panitumumab" @default.
• W4361954181 doi "https://doi.org/10.1158/1535-7163.c.6531585.v1" @default.
• W4361954181 hasPublicationYear "2023" @default.
• W4361954181 type Work @default.
• W4361954181 citedByCount "0" @default.
• W4361954181 crossrefType "posted-content" @default.
• W4361954181 hasAuthorship W4361954181A5005996455 @default.
• W4361954181 hasAuthorship W4361954181A5018249388 @default.
• W4361954181 hasAuthorship W4361954181A5021293751 @default.
• W4361954181 hasAuthorship W4361954181A5022268901 @default.
• W4361954181 hasAuthorship W4361954181A5022600083 @default.
• W4361954181 hasAuthorship W4361954181A5038836690 @default.
• W4361954181 hasAuthorship W4361954181A5047916176 @default.
• W4361954181 hasAuthorship W4361954181A5063512998 @default.
• W4361954181 hasConcept C121608353 @default.
• W4361954181 hasConcept C126322002 @default.
• W4361954181 hasConcept C150903083 @default.
• W4361954181 hasConcept C159654299 @default.
• W4361954181 hasConcept C203014093 @default.
• W4361954181 hasConcept C207001950 @default.
• W4361954181 hasConcept C2776146153 @default.
• W4361954181 hasConcept C2778332735 @default.
• W4361954181 hasConcept C2779438470 @default.
• W4361954181 hasConcept C2779931791 @default.
• W4361954181 hasConcept C2779998722 @default.
• W4361954181 hasConcept C502942594 @default.
• W4361954181 hasConcept C526805850 @default.
• W4361954181 hasConcept C542903549 @default.
• W4361954181 hasConcept C71924100 @default.
• W4361954181 hasConcept C86803240 @default.
• W4361954181 hasConceptScore W4361954181C121608353 @default.
• W4361954181 hasConceptScore W4361954181C126322002 @default.
• W4361954181 hasConceptScore W4361954181C150903083 @default.
• W4361954181 hasConceptScore W4361954181C159654299 @default.
• W4361954181 hasConceptScore W4361954181C203014093 @default.
• W4361954181 hasConceptScore W4361954181C207001950 @default.
• W4361954181 hasConceptScore W4361954181C2776146153 @default.
• W4361954181 hasConceptScore W4361954181C2778332735 @default.
• W4361954181 hasConceptScore W4361954181C2779438470 @default.
• W4361954181 hasConceptScore W4361954181C2779931791 @default.
• W4361954181 hasConceptScore W4361954181C2779998722 @default.
• W4361954181 hasConceptScore W4361954181C502942594 @default.
• W4361954181 hasConceptScore W4361954181C526805850 @default.
• W4361954181 hasConceptScore W4361954181C542903549 @default.
• W4361954181 hasConceptScore W4361954181C71924100 @default.
• W4361954181 hasConceptScore W4361954181C86803240 @default.
• W4361954181 hasLocation W43619541811 @default.
• W4361954181 hasOpenAccess W4361954181 @default.
• W4361954181 hasPrimaryLocation W43619541811 @default.
• W4361954181 hasRelatedWork W2006928910 @default.
• W4361954181 hasRelatedWork W2088713834 @default.
• W4361954181 hasRelatedWork W2171311886 @default.
• W4361954181 hasRelatedWork W2361331618 @default.
• W4361954181 hasRelatedWork W2391121226 @default.
• W4361954181 hasRelatedWork W2411204912 @default.
• W4361954181 hasRelatedWork W2416474089 @default.
• W4361954181 hasRelatedWork W2480998974 @default.
• W4361954181 hasRelatedWork W2593180677 @default.
• W4361954181 hasRelatedWork W3029390418 @default.
• W4361954181 isParatext "false" @default.
• W4361954181 isRetracted "false" @default.
• W4361954181 workType "article" @default.